¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hexose monophosphate shunt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® shunt ÇÑ±Û Áö¸§±æ, Áö¸§¼ú, ´Ü¶ô
¼³¸í   
  1. ÇÑÂÊÀ¸·Î µ¹¾Æ°¡´Ù, ÀüȯÇÏ´Ù, ¿ìȸÇÏ´Ù. 2. Ç÷°ü°£ÀÇ Åë·Î ¶Ç´Â ¿¬°á.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate
    À°Åº´çÀÏÀλê
  • cyclic adenosine monophosphate
    °í¸®ÇüAMP
  • guanosine monophosphate
    ÀÏÀλ걸¾Æ³ë½Å
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®
  • bypass shunt
    ¿ìȸ¼ÇÆ®
  • cardiovascular shunt
    ½ÉÀåÇ÷°ü¼ÇÆ®
  • intracardiac shunt
    ½ÉÀå³»¼ÇÆ®
  • left-to-right shunt
    Á¿ì¼ÇÆ®
  • lumboperitoneal shunt
    ¿äÃߺ¹°­¼ÇÆ®
  • mesocaval shunt
    ´ëÁ¤¸Æ°£¸·¼ÇÆ®
  • mesocaval shunt operation
    ´ëÁ¤¸Æ°£¸·¼ÇÆ®¼ö¼ú
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸Æ¼ÇÆ®
  • portocaval shunt operation
    ¹®¸Æ´ëÁ¤¸Æ¼ÇÆ®¼ö¼ú
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼ÇÆ®
  • peritoneovenous shunt
    º¹°­Á¤¸Æ¼ÇÆ®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • shunt circuit
    Áö¸§±æ
  • portocaval shunt operation
    ¹®¸Æ´ëÁ¤¸ÆÁö¸§¼ú, ¹®¸Æ´ëÁ¤¸Æ¿¬°á¼ú
  • shunt operation
    Áö¸§¼ú, ´Ü¶ô¼ú, ¼ÇÆ®¼ö¼ú
  • shunt
    Áö¸§±æ, Áö¸§¼ú, ¼ÇÆ®, »çÀÕ±æ
  • lumboperitoneal shunt
    ¿äÃߺ¹°­Áö¸§¼ú
  • peritoneovenous shunt
    º¹°­Á¤¸ÆÁö¸§¼ú, ¹è¸·Á¤¸ÆÁö¸§¼ú
  • right to left shunt
    ¿À¸¥¿ÞÁö¸§±æ
  • transjugular intrahepatic portosystemic shunt
    ¸ñÁ¤¸Æ°æÀ¯°£¼Ó¹®¸ÆÀü½Å¼øÈ¯Áö¸§¼ú, ¸ñÁ¤¸Æ°æÀ¯°£¼Ó¹®¸ÆÀü½Å¼øÈ¯¿¬°á¼ú
  • ventriculoperitoneal shunt
    ³ú½Çº¹°­Áö¸§¼ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate
    À°Åº´çÀÏÀλê
  • cyclic adenosine monophosphate
    °í¸®¿¡ÀÌ¿¥ÇÇ
  • arteriovenous shunt
    µ¿Á¤¸ÆÁö¸§±æ, µ¿Á¤¸ÆÁö¸§¼ú
  • bypass shunt
    ¿ìȸ·ÎÁö¸§±æ, ¿ìȸ·ÎÁö¸§¼ú
  • cardiaovascular shunt
    ½ÉÀåÇ÷°üÁö¸§±æ
  • shunt circuit
    Áö¸§±æ
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • intracardiac shunt
    ½ÉÀå³»Áö¸§±æ
  • mesocaval shunt operation
    âÀÚ°£¸·´ëÁ¤¸Æ¿¬°á¼ú, Àå°£¸·Á¤¸Æ´ëÁ¤¸Æ¿¬°á¼ú
  • shunt malfunction
    Áö¸§±æ±â´ÉÀå¾Ö
  • shunt operation
    Áö¸§¼ú, ´Ü¶ô¼ö¼ú
  • paracellular shunt
    ¼¼Æ÷ÁÖÀ§Áö¸§±æ
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸ÆÁö¸§(¼ú), ¹®¸Æ´ëÁ¤¸Æ¿¬°á(¼ú)
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼øÈ¯Áö¸§¼ú, ¹®¸ÆÀü½Å¼øÈ¯¿¬°á¼ú
  • renal shunt
    ÄáÆÏÇ÷·ùÁö¸§±æ, ½ÅÀåÇ÷·ùÁö¸§±æ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hexose monophosphate shunt
    À°Åº´çÀÏÀλ꿰ȸ·Î
  • hexose monophosphate shunt
    ÀÏÀλêÇí¼Ò½º¼ÇÆ®<--´Ü¶ô>
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate
    ÀÏÀλêÇí¼Ò½º.
  • Guanosine monophosphate (GMP)
    ÀÏÀλ걸¾Æ³ë½Å
  • adenosine 5-monophosphate
    ¾Æµ¥³ë½Å 5-ÀÏÀλ꿰
  • adenosine monophosphate
    ÀÏÀÎ»ê¾Æµ¥³ë½Å
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
  • Torkildsons shunt
    Åäųµå½¼´Ü¶ô.
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­Ó­Õ©)
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­´Ü¶ô).
  • portacaval shunt
    ¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ(¼ú)(¹®¸Æ´ëÁ¤¸Æ¹®ÇÕ¼ú).
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
  • portosystemic shunt
    ¹®¸ÆÀü½Å¼øÈ¯¹®ÇÕ¼ú(Ú¦Øæîïãóâàü»Ùüùêâú), ¹®¸ÆÀü½Å¼øÈ¯¼ÇÆ®((Ú¦Øæîïãóâàü»¡­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate shunt
    ÀÏÀλêÇí¼Ò½º¼ÇÆ®<--´Ü¶ô>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate
    ÀÏÀλêÇí¼Ò½º.
  • adenosine 5-monophosphate
    ¾Æµ¥³ë½Å 5-ÀÏÀλ꿰
  • adenosine monophosphate
    ÀÏÀÎ»ê¾Æµ¥³ë½Å
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
  • cyclic adenosine monophosphate
    °í¸® AMP
  • thymolphthalein monophosphate
    Ƽ¸ôÅ»·¹ÀÎÀÏÀλ꿰
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­Ó­Õ©)
  • arteriovenous shunt
    µ¿Á¤¸Æ¼ÇÆ®, µ¿Á¤¸Æ´Ü¶ô(¡­´Ü¶ô).
  • bypass shunt
    ¿ìȸ·Î ´Ü¶ô(éæüÞÖØÓ­Õ©).
  • bypass shunt
    ȸ·Î°£µµ, ȸ·Î´Ü¶ô(ȸ·Î´Ü¶ô), ¿ìȸ·Î´Ü¶ô.
  • bypass shunt
    ¼øÈ­ [½Å¿Ü,ÈäºÎ]ȸ ·Î°£µµ, ȸ·Î´Ü¶ô(üßÖØÓ­Õ©), ¿ìȸ·Î´Ü¶ô.
  • cardiac shunt
    ½É´Ü¶ô(ãýÓ­Õ©)
  • intracardiac shunt
    ½ÉÀå³»´Ü¶ô(¡­Ó­Õ©).
  • juxtamedullary shunt
    (¼öÁú)±ÙÁ¢ºÎ´Ü¶ô(âÐòõÐÎïÈݻӭթ).
  • left-to-right shunt
    Á¿ì¼ÇÆ®(ñ§éÓ¡­)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hexose monophosphate oxidative pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º »êÈ­°æ·Î (ß«ûùÌèÖØ)
  • hexose monophosphate pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º °æ·Î(ÌèÖØ)
  • hoxose monophosphate shunt
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º ºÐ·Î(ÝÂÖØ)
  • hexose
    Çí¼Ò½º
  • hexose diphosphate pathway
    ÀÌÀλê(ì£×òß«) Çí¼Ò½º °æ·Î (ÌèÖØ)
  • GABA shunt
    GABA ºÐ·Î(ÝÂÖØ)
  • HMP shunt
    HMP ºÐ·Î(ÝÂÖØ)
  • metabolic shunt
    ´ë»ç ºÐ·Î(ÓÛÞóÝÂÖØ)
  • shunt
    ºÐ·Î(ÝÂÖØ)
  • adenosine monophosphate
    ÀÏÀλê(ìéìÝß«)¾Æµ¥³ë½Å
  • "adenosine-3',5'-cyclic monophosphate"
    ¾Æµ¥³ë½Å-3'-5'-°í¸® ÀÏ(ìé)Àλ꿰(×òß«ç¤)
  • "uanosine-3', 5'-cyclic monophosphate"
    "±¸¾Æ³ë½Å-3`,5'-°í¸® ÀÏÀλê(ìé×òß«)"
  • nucleoside cyclic monophosphate
    °í¸® ÀÏÀλê(ìé×òß«) ´©Å¬¸®¿À»çÀ̵å
  • nucleoside monophosphate
    ÀÏÀλê(ìé×òß«) ´©Å¬¸®¿À»çÀ̵å
  • nucleoside monophosphate kinase
    ÀÏÀλê(ìé×òß«) ´©Å¬¸®¿À»çÀ̵å Ä«À̳×À̽º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arterioportal shunt
    µ¿¸Æ¹®¸Æ´Ü¶ô
  • intracardiac shunt
    ½ÉÀå³»´Ü¶ô
  • shunt
    ¼ÇÆ®, ´Ü¶ô
  • splenorenal shunt
    ºñ½ÅÁ¤¸ÆÀü·ù¼ú
  • TIPS [=transjugular intrahepatic portosystemic shunt]
    °æ°æÁ¤¸Æ°£³»¹®¸ÆÁ¤¸Æ´Ü¶ô¼ú
  • transjugular intrahepatic portosystemic shunt [=TIPS]
    °æ°æÁ¤¸Æ°£³»¹®¸ÆÁ¤¸Æ´Ü¶ô¼ú
  • ventriculocaval shunt
    ³ú½Ç»ó´ëÁ¤¸Æ´Ü¶ô(¼ú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HMP Shunt Hexose Mono-Phosphate Shunt
TMP thiamine monophosphate; thymidine monophosphate; thymidine-5'-monophosphate; thymolphthalein monopho...
HMPS hexose monophosphate shunt
HMS hexose monophosphate shunt; hypermobility syndrome
HMP hexose monophosphate pathway; hot moist packs
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HMPS Hexose monophosphate shunt
HMS Hexose-monophosphate shunt
HMP Hexose monophosphate
HMP Hexose monophosphate pathway
DSRS Distal splenorenal shunt
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hexose monophosphate shunt
    ÀÏÀλê Çí¼Ò½º ¼ÇÆ®
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hexose
    Çí¼Ò½º
    ÇÑ ºÐÀÚ Áß¿¡ 6°³ÀÇ Åº¼Ò ¿øÀÚ¸¦ ÇÔÀ¯ÇÑ ´Ü´ç·ù.
  • adenosine 5-monophosphate
    ¾Æµ¥³ë½Å 5-ÀÏÀλ꿰
  • adenosine monophosphate
    ¾Æµ¥³ë½Å ÀÏ Àλê, ÀÏÀÎ»ê ¾Æµ¥³ë½Å
    ¾Æµ¥´Ñ°ú ¸®º¸½ºÀÇ °áÇÕ¹°ÀÎ ¾Æµ¥³ë½Å¿¡ ÀλêÀÌ ¿¡½ºÅ׸£ °áÇÕÇÑ ¸ð³ë´ºÅ¬·¹¿ÀŸÀ̵åÀÇ ÀÏÁ¾. ÀλêÈ­µÇ¾î °í¿¡³ÊÁö È­ÇÕ¹°ÀÎ ¾Æµ¥³ë½Å 2Àλê, 3ÀλêÀÌ »ý±ä´Ù. ÀλêÀÌ ¸®º¸½ºÀÇ C5 Å͹̳¯¿¡ °áÇÕÇÑ °Í°ú C3 Å͹̳¯¿¡ °áÇÕÇÑ 2Á¾ÀÇ À̼ºÃ¼°¡ Á¸ÀçÇϰí ÀüÀÚ´Â ±ÙÀ° µî¿¡¼­ º¼ ¼ö ÀÖÀ¸¸ç, ÈÄÀÚ´Â È¿¸ð ÇÙ»êÀÇ °¡¼öºÐÇØ µîÀ¸·Î ¾ò°Ô µÈ´Ù. ¾çÀÚ°¡ ¸ðµÎ ¹°¿¡ Àß ³ìÁö ¾Ê´Â ħ»ó °áÁ¤ÀÌ´Ù.
  • anteriovenous shunt appliance
    µ¿Á¤¸Æ Ãø·ÎÀåÄ¡
  • arteriovenous shunt
    µ¿Á¤¸Æ ´Ü¶ô
  • intracardiac shunt
    ½ÉÀå ³» ´Ü¶ô
  • juxtamedullary shunt
    ¼öÁú ±ÙÁ¢ºÎ ´Ü¶ô
  • shunt cyanosis
    ºÐÇÕ¼º û»öÁõ
    »ê¼Ò ºÒÆ÷È­ Ç÷¾×ÀÌ ½ÉÀå ¶Ç´Â ´ëÇ÷°üÀÇ µ¿¸Æ Ç÷¾×¿¡ È¥ÇÕµÊÀ¸·Î½á ¹ß»ýÇϴ û»öÁõ.
  • shunt-in personality
    ÀÚÆó¼º ÀΰÝ
  • splenorenal shunt
    ºñ½ÅÁ¤¸Æ Àü·ù¼ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
hexose monophosphate shunt The main metabolic pathway in activated neutrophils, rendering them relatively insensitive to inhibitors of oxidative phosphorylation. Congenital deficiency of the first enzyme in the shunt, glucose 6 phosphate dehydrogenase, produces a sensitivity to infection similar to that seen in chronic granulomatous disease.
(18 Nov 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
hexose monophosphate pathway <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
pentose monophosphate shunt <biochemistry> A pathway of hexose oxidation in which glucose-6-phosphate undergoes two successive oxidations by NADP, the final one being an oxidative decarboxylation to form a pentose phosphate.
Diverges from this when glucose-6-phosphate is oxidized to ribose 5 phosphate by the enzyme glucose-6 phosphate dehydrogenase. This step reduces NADP to NADPH, generating a source of reducing power in cells for use in reductive biosyntheses.
In plants, part of the pathway functions in the formation of hexoses from carbon dioxide in photosynthesis. Also important as source of pentoses, for example for nucleic acid biosynthesis. This pathway is the main metabolic pathway in neutrophils, congenital deficiency in the pathway produces sensitivity to infection.
Alternative metabolic route to Embden Meyerhof pathway for breakdown of glucose.
(18 Nov 1997)
hexose Monosaccharide containing six carbon atoms, for example glucose, galactose, mannose.
(18 Nov 1997)
hexose-1-phosphate uridylyltransferase <enzyme> An enzyme that catalyses the transfer of ump from udpglucose to galactose 1-phosphate, forming udpgalactose and glucose 1-phosphate. Deficiency in this enzyme is the major cause of galactosaemia.
Chemical name: UDPglucose:alpha-D-galactose-1-phosphate uridylyltransferase
Registry number: EC 2.7.7.12
(12 Dec 1998)
hexose monphosphate pathway A metabolic pathway present in a wide range of prokaryotic and eukaryotic microorganisms as well as in plants and animals, it involves the oxidative decarboxylation of glucose-6-phosphate, via 6 phosphogluconate, to ribulose 5-phosphate, followed by a series of reversible, non-oxidative interconversions whereby hexose and triose phosphates are formed from pentose phosphates.
(09 Oct 1997)
hexose phosphatase <enzyme> May be an aspect of acid phosphatase, EC 3.1.3.2
Registry number: EC 3.1.3.-
(26 Jun 1999)
hexose phosphate synthetase <enzyme> Ribulosephosphate formaldehyde gives d-erythro-l-glycero-3-hexulose
Registry number: EC 4.1.2.-
Synonym: 3-hexulose phosphate synthase, d-arabino-3-hexulose 6-phosphate formaldehyde-lyase, 3-hexulosephosphate synthase, d-arabino-3-hexulose-6-phosphate-lysase, hexulose-6-phosphate synthase, hump synthase
(26 Jun 1999)
udpglucose-hexose-1-phosphate uridylyltransferase <enzyme> An enzyme that catalyses the transfer of ump from udpglucose to galactose 1-phosphate, forming udpgalactose and glucose 1-phosphate. Deficiency in this enzyme is the major cause of galactosaemia.
Chemical name: UDPglucose:alpha-D-galactose-1-phosphate uridylyltransferase
Registry number: EC 2.7.7.12
(12 Dec 1998)
utp-hexose-1-phosphate uridylyltransferase <enzyme> An enzyme that catalyses the synthesis of udpgalactose from utp and galactose-1-phosphate. It is present in low levels in foetal and infant liver, but increases with age, thereby enabling galactosaemic infants who survive to develop the capacity to metabolise galactose.
Chemical name: UTP:alpha-D-hexose-1-phosphate uridylyltransferase
Registry number: EC 2.7.7.10
(12 Dec 1998)
adenosine 3',5'-cyclic monophosphate An activator of phosphorylase kinase and an effector of other enzymes, formed in muscle from ATP by adenylate cyclase and broken down to 5'-AMP by a phosphodiesterase; sometimes referred to as the "second messenger." A related compound (2',3') is also known.
Synonym: cyclic adenylic acid, cyclic AMP, cyclic phosphate.
Acronym: cAMP
(05 Mar 2000)
adenosine monophosphate <chemical> Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
Chemical name: 5'-Adenylic acid
(12 Dec 1998)
guanosine 5'-monophosphate A major component of ribonucleic acids.
Synonym: guanine ribonucleotide, guanosine 5'-monophosphate.
Guanylic acid reductase (GMP reductase), an enzyme that catalyses the reaction of GMP with NADPH producing IMP, NH3, and NADP+; a part of the purine salvage pathway.
Guanylic acid synthetase (GMP synthetase), an enzyme catalyzing the reaction of l-glutamine, XMP, and ATP to produce GMP, l-glutamate, AMP, and pyrophosphate; a key step in purine biosynthesis.
Acronym: GMP
(05 Mar 2000)
guanosine monophosphate A ribonucleotide which consists of the nitrogenous base guanine linked to the sugar ribose and which has a phosphate group attached to the 5th carbon atom of the ribose.
(09 Oct 1997)
cyclic guanosine monophosphate A cyclic version of the nucleotide guanosine monophosphate. It plays a role in communicating vision from the eyes to the brain.
(09 Oct 1997)
cyclic uridine 3',5'-monophosphate A cyclic nucleotide involved in metabolic regulation; inhibits the growth of some tumours.
(05 Mar 2000)
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 1 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cyclic adenosine monophosphate
    =CYCLIC AMP
  • hexose
    6ź´ç
  • shunt
    À» ´Ý´Ù
  • shunt
    ¿·À¸·Î µ¹¸®´Ù;Á¦°ÅÇÏ´Ù;ÇÑÂÊÀ¸·Î ºñŰ´Ù;Ãø¼±¿¡ ³Ö´Ù;Àüö(ÀÔÇÑ)ÇÏ´Ù;ÇÑÂÊÀ¸·Î ºñŰ´Ù;Ãø¼±À¸·Î µé¾î°¡´Ù;Àüö(±â)ºÐ·Î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á